ATE443721T1 - Lipoprotein-regulierende medikamente - Google Patents

Lipoprotein-regulierende medikamente

Info

Publication number
ATE443721T1
ATE443721T1 AT07120518T AT07120518T ATE443721T1 AT E443721 T1 ATE443721 T1 AT E443721T1 AT 07120518 T AT07120518 T AT 07120518T AT 07120518 T AT07120518 T AT 07120518T AT E443721 T1 ATE443721 T1 AT E443721T1
Authority
AT
Austria
Prior art keywords
lsr
purified
ffa
isolated
binds
Prior art date
Application number
AT07120518T
Other languages
English (en)
Inventor
Bernard Bihain
Lydie Bougueleret
Frances Yen-Potin
Original Assignee
Merck Serono Biodevelopment
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9710088A external-priority patent/FR2767136B1/fr
Application filed by Merck Serono Biodevelopment, Inst Nat Sante Rech Med filed Critical Merck Serono Biodevelopment
Application granted granted Critical
Publication of ATE443721T1 publication Critical patent/ATE443721T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT07120518T 1997-08-06 1998-08-06 Lipoprotein-regulierende medikamente ATE443721T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9710088A FR2767136B1 (fr) 1997-08-06 1997-08-06 Recepteur complexe lsr, activite, clonage, et applications au diagnostic, a la prevention et/ou au traitement de l'obesite et des risques ou complications associes
FR9805032A FR2767135B1 (fr) 1997-08-06 1998-04-22 Recepteur complexe lsr, activite, clonage, et application au diagnostic, a la prevention et/ou au traitement de d'obesite et des risques ou complications associes

Publications (1)

Publication Number Publication Date
ATE443721T1 true ATE443721T1 (de) 2009-10-15

Family

ID=26233732

Family Applications (3)

Application Number Title Priority Date Filing Date
AT07120518T ATE443721T1 (de) 1997-08-06 1998-08-06 Lipoprotein-regulierende medikamente
AT98936611T ATE256146T1 (de) 1997-08-06 1998-08-06 Klonierung und verwendung des lsr-rezeptors
AT98936610T ATE378354T1 (de) 1997-08-06 1998-08-06 Lipoprotein-regulierende arzneimittel

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT98936611T ATE256146T1 (de) 1997-08-06 1998-08-06 Klonierung und verwendung des lsr-rezeptors
AT98936610T ATE378354T1 (de) 1997-08-06 1998-08-06 Lipoprotein-regulierende arzneimittel

Country Status (13)

Country Link
US (8) US6344441B1 (de)
EP (4) EP1003783B1 (de)
JP (3) JP3726969B2 (de)
AT (3) ATE443721T1 (de)
AU (2) AU754942B2 (de)
CA (2) CA2298849A1 (de)
CY (1) CY1107808T1 (de)
DE (3) DE69838720T2 (de)
DK (2) DK0964870T3 (de)
ES (2) ES2296339T3 (de)
FR (1) FR2767135B1 (de)
PT (2) PT1003783E (de)
WO (2) WO1999007737A2 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6469158B1 (en) * 1992-05-14 2002-10-22 Ribozyme Pharmaceuticals, Incorporated Synthesis, deprotection, analysis and purification of RNA and ribozymes
US6525174B1 (en) 1997-06-06 2003-02-25 Human Genome Sciences, Inc. Precerebellin-like protein
FR2767135B1 (fr) * 1997-08-06 2002-07-12 Genset Sa Recepteur complexe lsr, activite, clonage, et application au diagnostic, a la prevention et/ou au traitement de d'obesite et des risques ou complications associes
US20020106728A1 (en) * 2000-06-20 2002-08-08 Genentech, Inc. NS4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
WO2000026363A1 (en) * 1998-11-04 2000-05-11 Genset GENOMIC AND COMPLETE cDNA SEQUENCES OF HUMAN ADIPOCYTE-SPECIFIC APM1 AND BIALLELIC MARKERS THEREOF
DE60041912D1 (de) * 1999-02-10 2009-05-14 Serono Genetics Inst Sa Polymorphe marker des lsr-gens
CA2370609A1 (en) * 1999-04-20 2000-10-26 Zymogenetics, Inc. Adipocyte complement related protein homolog zacrp3
JP2002541846A (ja) * 1999-04-20 2002-12-10 ザイモジェネティクス，インコーポレイティド 脂肪細胞補体関連タンパク質同族体ｚａｃｒｐ２
CA2388417A1 (en) * 1999-09-22 2001-03-29 Genset Methods of screening for compounds that modulate the lsr-leptin interaction and their use in the prevention and treatment of obesity-related diseases
WO2001032868A1 (en) * 1999-11-04 2001-05-10 Genset Apm1 biallelic markers and uses thereof
US20020058617A1 (en) 2000-01-14 2002-05-16 Joachim Fruebis OBG3 globular head and uses thereof for decreasing body mass
US6579852B2 (en) 2000-01-14 2003-06-17 Genset S.A. OBG3 globular head and uses thereof for decreasing body mass
US7338787B2 (en) * 2000-01-14 2008-03-04 Serono Genetics Institute S.A. Nucleic acids encoding OBG3 globular head and uses thereof
US6989367B2 (en) 2000-01-14 2006-01-24 Genset S.A. OBG3 globular head and uses thereof
US6566332B2 (en) 2000-01-14 2003-05-20 Genset S.A. OBG3 globular head and uses thereof for decreasing body mass
PT1248849E (pt) * 2000-01-14 2008-09-08 Serono Genetics Inst Sa Cabeça globular obg3 e suas utilizações para reduzir a massa corporal
JP2003535104A (ja) * 2000-05-31 2003-11-25 ジェンセット 筋量および筋分化の増加を促進させるためのａｃｒｐ３０球状ヘッドの使用方法
IL153927A0 (en) * 2000-07-18 2003-07-31 Genset Sa Genomic maps comprising biallelic markers, new such markers and the use of biallelic markers
EP1372699A4 (de) * 2001-02-26 2006-05-24 Univ Sydney Verfahren zur verbesserung der wachstumsleistung eines tieres
CA2440144A1 (en) * 2001-03-14 2002-09-19 Oklahoma Medical Research Foundation Methods for reducing fat by administration of adiponectin
JP4547696B2 (ja) * 2001-06-07 2010-09-22 第一三共株式会社 肝硬変予防・治療剤
US20050054565A1 (en) * 2001-07-31 2005-03-10 John Lucas Agonists and antagonists of moxifin for the treatment of metabolic disorders
US7276342B2 (en) * 2001-08-02 2007-10-02 Serono Genetics Institute S.A. Xobesin agonists and antagonists for the treatment of metabolic disorders
WO2003041738A1 (en) * 2001-11-15 2003-05-22 Genset S.A. Treatment of metabolic disorders with xitar agonists and antagonists
AU2002339691A1 (en) * 2001-11-29 2003-06-10 Genset Agonists and antagonists of prolixin for the treatment of metabolic disorders
EP1474445A4 (de) * 2002-01-18 2007-02-21 Protemix Corp Ltd Glykoisoformen vom adiponektin und deren verwendung
US6852693B2 (en) 2002-02-07 2005-02-08 Blm Group Compositions and methods for promoting lipid mobilization in humans
EP1537875B1 (de) * 2002-05-24 2009-08-26 Japan Science and Technology Agency C-terminale globulardomäne von adiponectin zur behandlung von arteriosklerose
ES2350573T3 (es) 2002-05-31 2011-01-25 Merck Serono Biodevelopment Sas Cabeza globular de obg3 ensanchada, homotrimérica y sus usos.
DE602004022632D1 (de) * 2003-01-09 2009-10-01 Beth Israel Hospital Verwendung von adiponectin zur diagnose von krebs
US8147561B2 (en) 2004-02-26 2012-04-03 Endosphere, Inc. Methods and devices to curb appetite and/or reduce food intake
US8585771B2 (en) 2004-02-26 2013-11-19 Endosphere, Inc. Methods and devices to curb appetite and/or to reduce food intake
US7931693B2 (en) * 2004-02-26 2011-04-26 Endosphere, Inc. Method and apparatus for reducing obesity
US20060127468A1 (en) * 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
WO2006062422A1 (en) * 2004-12-10 2006-06-15 Protemix Corporation Limited Glyponectin (glycosylated adiponectin) for the treatment of diseases and conditions
JP2008526885A (ja) * 2005-01-07 2008-07-24 ゼンコア アディポネクチン変異体
US7592423B2 (en) * 2005-01-07 2009-09-22 Xencor, Inc. Globular adiponectin variants
US7749956B2 (en) * 2005-01-07 2010-07-06 Xencor, Inc. Method of treatment using adiponectin variants
US7678886B2 (en) * 2005-01-07 2010-03-16 Xencor, Inc. Pharmaceutical compositions of adiponectin variants and methods of storage
WO2006104964A2 (en) * 2005-03-28 2006-10-05 University Of Louisville Research Foundation, Inc. Inhibition of wet type age related macular degeneration (amd) by adiponectin or acrp 30
US20070054359A1 (en) * 2005-07-11 2007-03-08 Jonathan Zalevsky Rational Chemical Modification of Adiponectin Variants
US20090291091A1 (en) * 2005-07-29 2009-11-26 Laboratoires Serono Sa Use of the globular domain of acrp30 for the preparation of a medicament for the prevention and/or treatment of thrombosis-related diseases
US9060835B2 (en) 2006-05-26 2015-06-23 Endosphere, Inc. Conformationally-stabilized intraluminal device for medical applications
US20110137227A1 (en) 2007-07-16 2011-06-09 Mckinley James T Methods and devices for delivering or delaying lipids within a duodenum
US8355877B2 (en) * 2007-12-19 2013-01-15 Eli Lilly And Company System for predicting responsiveness to a pharmaceutical therapy for obesity
JP5429736B2 (ja) * 2009-04-13 2014-02-26 国立大学法人神戸大学 タイトジャンクション調節剤
CA2827643C (en) 2011-02-18 2019-05-07 Kythera Biopharmaceuticals, Inc. Treatment of submental fat
US9409987B2 (en) * 2011-04-15 2016-08-09 Compugen Ltd Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
EP2744830A4 (de) * 2012-06-21 2015-06-17 Compugen Ltd Lsr-antikörper und verwendungen davon zur behandlung von krebs
CN104004066B (zh) * 2013-02-26 2017-05-31 上海市第一人民医院 预防或抑制炎症反应和血管新生的小分子多肽及其应用
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
EP3088001B1 (de) * 2013-12-27 2020-02-12 National University Corporation Kochi University Antikörpern gegen lipolysis stimulated liporotein receptor zur behandlung von eierstockkrebs
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN120643715A (zh) * 2025-06-16 2025-09-16 滨州医学院 巨噬细胞Angulin-1在制备预防和/或治疗动脉粥样硬化及相关疾病的药物、诊断产品中的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US111500A (en) * 1871-01-31 Improvement in repeating fire-arms
US67881A (en) * 1867-08-20 Geobge p
US77051A (en) * 1868-04-21 peters
US5543394A (en) * 1986-07-01 1996-08-06 Genetics Institute, Inc. Bone morphogenetic protein 5(BMP-5) compositions
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
NL9100132A (nl) * 1991-01-25 1992-08-17 Ingeny Bv Werkwijze voor het detecteren van dna sequentievariatie.
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US5691447A (en) 1995-03-24 1997-11-25 Tanox Biosystems, Inc. GC1q receptor, HIV-1 gp120 region binding thereto, and related peptides and targeting antibodies
FR2733762B1 (fr) 1995-05-02 1997-08-01 Genset Sa Methode de couplage specifique de la coiffe de l'extremite 5' d'un fragment d'arnm et preparation d'arnm et d'adnc complet
US5869330A (en) * 1995-06-05 1999-02-09 Whitehead Institute For Biomedical Research DNA encoding a novel serum protein produced exclusively in adipocytes
CA2244693A1 (en) * 1996-01-23 1997-07-31 Progenitor, Inc. Methods for using the obese gene and its gene product to stimulate hematopoietic development
US6116126A (en) 1996-07-10 2000-09-12 Van Den Bulcke; Marc Method and machine for making profile pieces
US6126939A (en) * 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
EP0941366A2 (de) 1996-11-06 1999-09-15 Whitehead Institute For Biomedical Research Biallelische marker
PL338139A1 (en) * 1997-07-18 2000-09-25 Zymogenetics Inc Protein homologues specific for adipocytes
FR2767135B1 (fr) 1997-08-06 2002-07-12 Genset Sa Recepteur complexe lsr, activite, clonage, et application au diagnostic, a la prevention et/ou au traitement de d'obesite et des risques ou complications associes
JP3492999B2 (ja) 1997-08-26 2004-02-03 ザイモジェネティクス，インコーポレイティド 脂肪細胞特異的タンパク質の同族体
EP1033134B8 (de) 1997-10-29 2007-09-19 Otsuka Pharmaceutical Co., Ltd. Compositions zur inhibierung der proliferation glatter muskulatur und verfahren zur diagnose von arteriosklerose
US6566332B2 (en) * 2000-01-14 2003-05-20 Genset S.A. OBG3 globular head and uses thereof for decreasing body mass
US6579852B2 (en) 2000-01-14 2003-06-17 Genset S.A. OBG3 globular head and uses thereof for decreasing body mass
US6989367B2 (en) 2000-01-14 2006-01-24 Genset S.A. OBG3 globular head and uses thereof
US20020058617A1 (en) 2000-01-14 2002-05-16 Joachim Fruebis OBG3 globular head and uses thereof for decreasing body mass
US20030215836A1 (en) * 2000-03-17 2003-11-20 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
US20030224501A1 (en) * 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
US6867189B2 (en) * 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
US20050054565A1 (en) * 2001-07-31 2005-03-10 John Lucas Agonists and antagonists of moxifin for the treatment of metabolic disorders
US7276342B2 (en) * 2001-08-02 2007-10-02 Serono Genetics Institute S.A. Xobesin agonists and antagonists for the treatment of metabolic disorders
AU2002339691A1 (en) * 2001-11-29 2003-06-10 Genset Agonists and antagonists of prolixin for the treatment of metabolic disorders

Also Published As

Publication number Publication date
AU8556498A (en) 1999-03-01
PT1003783E (pt) 2007-12-06
ATE378354T1 (de) 2007-11-15
WO1999007737A2 (fr) 1999-02-18
EP1903057B1 (de) 2009-09-23
DE69820419D1 (de) 2004-01-22
WO1999007737A3 (fr) 1999-06-10
FR2767135A1 (fr) 1999-02-12
PT964870E (pt) 2004-02-27
DE69820419T2 (de) 2004-11-25
US7919091B2 (en) 2011-04-05
US20040077051A1 (en) 2004-04-22
ATE256146T1 (de) 2003-12-15
AU8556398A (en) 1999-03-01
DE69841186D1 (de) 2009-11-05
EP0964870A2 (de) 1999-12-22
US20090263847A1 (en) 2009-10-22
US6635431B1 (en) 2003-10-21
US7291709B2 (en) 2007-11-06
AU754942B2 (en) 2002-11-28
AU745607B2 (en) 2002-03-21
EP1375516A3 (de) 2004-06-09
WO1999007736A2 (en) 1999-02-18
US20110165166A1 (en) 2011-07-07
US6344441B1 (en) 2002-02-05
EP1003783A2 (de) 2000-05-31
EP1375516A2 (de) 2004-01-02
CA2274302A1 (fr) 1999-02-18
CA2298849A1 (en) 1999-02-18
EP1003783B1 (de) 2007-11-14
DE69838720D1 (de) 2007-12-27
DK0964870T3 (da) 2004-03-08
US20020165154A1 (en) 2002-11-07
US20020151498A1 (en) 2002-10-17
JP3726969B2 (ja) 2005-12-14
AU745607C (en) 2002-08-29
DE69838720T2 (de) 2008-10-30
JP2001512746A (ja) 2001-08-28
DK1003783T3 (da) 2008-01-02
ES2296339T3 (es) 2008-04-16
FR2767135B1 (fr) 2002-07-12
EP1903057A2 (de) 2008-03-26
ES2210786T3 (es) 2004-07-01
US20080249009A1 (en) 2008-10-09
JP2001512492A (ja) 2001-08-21
JP2005143508A (ja) 2005-06-09
CY1107808T1 (el) 2013-06-19
EP0964870B1 (de) 2003-12-10
US7220722B2 (en) 2007-05-22
US6946444B2 (en) 2005-09-20
WO1999007736A3 (en) 1999-05-20
EP1903057A3 (de) 2008-06-25

Similar Documents

Publication Publication Date Title
DE69841186D1 (de) Lipoprotein-regulierende Medikamente
UA42760C2 (uk) Спосіб спрямування клітинної імунної відповіді проти віл-інфікованої клітини ссавця,білковий мембранозв'язаний химерний рецептор,днк,яка кодує химерний рецептор,вектор,що її містить
ATE444361T1 (de) Il-17 und il-17r homologe polypeptide und deren therapeutische verwendungen
ATE25197T1 (de) Hybridproteinekodierende fusionierte gene, sie enthaltende klonierungsvektoren und deren verwendung.
FI855141A7 (fi) Rekombinantti-DNA-vektoreita, jotka kykenevät ilmaisemaan apoaequoriinia.
FI104180B1 (fi) Menetelmä polypeptidin vasta-aineen ekä IL-4 välittämien tilojen hoitoon tarkoitetun seoksen valmistamiseksi
ATE228534T1 (de) Struktur höherer ordnung und bindung von peptidnukleinsäuren
FI972390A0 (fi) Sytokiini nimeltä Lerk-7
ATE447583T1 (de) Polypeptide und dafür kodierende nukleinsäure
DE68926303D1 (de) Peptide und antikörper, die die integrin-ligandbindung inhibieren
EA199900869A1 (ru) Цитокин-подобный фактор 7 млекопитающих
PT101297A (pt) Factores mitogenicos gliais, sua preparacao e utilizacao
DK1017715T3 (da) Kimært polypeptid der omfatter fragment B af shiga-toksin og peptider af terapeutisk interesse
DE69735716D1 (de) Kappa/mu ähnliche proteintyrosinphosphatase, proteintyrosinphosphatase lambda
NO860421L (no) Sammensmeltet gen som koder for et hybridprotein.
PT1169442E (pt) Polipeptidos segregados e transmembranares e acidos nucleicos que os codificam
ATE426028T1 (de) Zellvolumenregulierte humane kinase h-sgk
NO944887L (no) Monoklonale antistoffer mot glykoprotein
DK0901526T3 (da) Cortistatin: neuropeptider, sammensætninger og metoder
TR200000288T2 (tr) İnsülin C-peptidin rekombinan ekspresyonu.
Getlawi et al. Chromaffin granule membrane glycoprotein IV is identical with Ac45, a membrane-integral subunit of the granule's H+-ATPase
DK0487229T3 (da) DNA, der koder for et protein, som binder til enhanceren for alfa-føtoproteingenet
DE69932644D1 (de) Menschliches Protein mit in vitro antiproliferativer Aktivität.
DE69032096D1 (de) Antikörper gegen das carboxy-terminale Peptid des Somatotropin-Bindungsproteins der Ratte
NO20015821D0 (no) Nye humane androgenreseptorvarianter

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties